India’s drug regulator CDSCO flagged 186 medicines, including paracetamol and diabetes drugs, as substandard in May 2025, raising serious concerns about drug safety and manufacturing practices.

New Delhi: The Drugs Controller General of India (DCGI) has directed the cosmetics industry to follow regulatory protocols, and warned against making “unusual claims” to younger-looking skin ...

India's apex drugs regulatory body, Central Drugs Standard Control Organisation (CDSCO), has directed drug controllers of all states and union territories to stop the manufacturing, sale and ...

They have also been asked to review their approval process for such fixed dose combination drugs (FDC) and ensure strict compliance of the provisions of the Drugs and Cosmetics Act 1940 and rules.

The Drugs & Cosmetics Act, 1940 gives the state drug inspectors the power to call for sales records (S. 18A & S.18B) of the NSQ batch and seize the NSQ drugs [S. 22(c)] so that they cannot be sold ...

This has resulted in a lack of uniform enforcement of the provision of NDCT Rules 2019 under the Drugs and Cosmetics Act 1940 across the country, the letter pointed out.

"It has come to the notice of this directorate that certain FDC drugs have been licensed for manufacture, sale, and distribution without prior evaluation of safety and efficacy as per the provision of ...

They have also been asked to review their approval process for such fixed dose combination (FDC) drugs and ensure strict compliance of the provisions of the Drugs and Cosmetics Act 1940 and rules.

India's drug regulatory body, CDSCO, has banned 35 fixed-dose combination drugs, ... of safety and efficacy as per the provision of NDCT Rules 2019 under the Drugs and Cosmetics Act 1940.